title: Defining optimum conditions for the ex vivo expansion of human umbilical cord blood cells. Influences of progenitor enrichment, interference with feeder layers, early-acting cytokines and agitation of culture vessels.
abstract: Ex vivo expansion of human umbilical cord blood cells (HUCBC) is explored by several investigators to enhance the repopulating potential of HUCBC. We performed experiments using either Ficoll-separated or CD34+-selected HUCBC from the same donation in serum-free medium. CD34-purified HUCBC were cultured on either human umbilical vein endothelial cells (HUVEC) or irradiated bone marrow-derived stroma cells (BMSC) with addition of different cytokines. In addition, we tested the expansion of HUCBC in culture vessels with continuous rotation. CD34 enrichment led to a significant increase in the expansion factor of CD34+ cells compared with unmanipulated HUCBC. BMSC were more efficient in amplifying early progenitors than HUVEC. Optimum results were reached by a combination of SCF, FLT-3L at 300 ng/ml and IL-3 at 50 ng/ml. No significant improvement in the expansion of CD34+/38- primitive progenitors could be obtained with other combinations. Addition of megakaryocyte-derived growth and development factor to each growth factor cocktail improved the expansion results. Continuous rotation of culture vessels did not ameliorate the expansion rate of the analyzed subsets. Culture conditions separating stroma and HUCBC by a semipermeable membrane improved the expansion factors of CD34+, CD34+/38-, and CD34+/41+ cells and CFU-GM compared with contact cultures. These data might be useful when designing culture systems for clinical scale ex vivo expansion of HUCBC.
authors.affiliation: Universitätsklinikum Carl Gustav Carus, Med. Klinik I, Dresden, Germany.
authors.forename: T
authors.initials: T
authors.lastname: Köhler
authors.forename: R
authors.initials: R
authors.lastname: Plettig
authors.forename: W
authors.initials: W
authors.lastname: Wetzstein
authors.forename: B
authors.initials: B
authors.lastname: Schaffer
authors.forename: R
authors.initials: R
authors.lastname: Ordemann
authors.forename: H O
authors.initials: HO
authors.lastname: Nagels
authors.forename: G
authors.initials: G
authors.lastname: Ehninger
authors.forename: M
authors.initials: M
authors.lastname: Bornhäuser
mesh_terms: D018952:Antigens, CD34 / Q000494:pharmacology; D018929:Cell Culture Techniques / Q000379:methods*; D002455:Cell Division; D016207:Cytokines / Q000494:pharmacology*; D005312:Fetal Blood / Q000166:cytology*; D005434:Flow Cytometry; D006412:Hematopoietic Stem Cells; D006801:Humans; D008747:Methylcellulose / Q000494:pharmacology; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000494:pharmacology; D019009:Proto-Oncogene Proteins c-kit / Q000494:pharmacology; D017154:Stromal Cells; D013926:Thrombopoietin
chemical_list: D018952:Antigens, CD34; D016207:Cytokines; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D008747:Methylcellulose; D013926:Thrombopoietin; D019009:Proto-Oncogene Proteins c-kit